Polycystic liver disease: An overview of pathogenesis, clinical manifestations and management

Orphanet Journal of Rare Diseases

Volumn 9, Issue 1, 2014, Pages

  Cnossen, Wybrich R ^a   Drenth, Joost P H ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Autosomal dominant polycystic kidney disease (ADPKD); Autosomal dominant polycystic liver disease (PCLD); Biliary tract disease; Cystogenesis; Ductal plate malformation (DPM); Hepatomegaly; Polycystic liver disease (PLD); Von Meyenburg complex (VMC)

Indexed keywords

SOMATOSTATIN;

ABDOMEN; ABDOMINAL DISTENSION; ABDOMINAL PAIN; ASCITES; AUTOSOMAL DOMINANT INHERITANCE; AUTOSOMAL RECESSIVE INHERITANCE; BILE DUCT DISEASE; CARDIOVASCULAR SYSTEM; CAROLI DISEASE; CELL DIFFERENTIATION; CILIATED EPITHELIUM; CLINICAL FEATURE; CYST RUPTURE; DIFFERENTIAL DIAGNOSIS; DISEASE SEVERITY; ECHOGRAPHY; END STAGE LIVER DISEASE; ENVIRONMENTAL FACTOR; EPIDEMIOLOGY; GENE MUTATION; GENETIC COUNSELING; GENETIC SCREENING; GERMLINE MUTATION; HETEROZYGOSITY LOSS; HUMAN; INFECTION; JAUNDICE; KIDNEY; KIDNEY FAILURE; KIDNEY POLYCYSTIC DISEASE; LIVER CYST; LIVER FAILURE; LIVER FUNCTION; LIVER HEMORRHAGE; LIVER POLYCYSTIC DISEASE; LIVER WEIGHT; MODIFIER GENE; MOLECULAR DIAGNOSTICS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PORTAL HYPERTENSION; PROGNOSIS; PROTEIN FUNCTION; QUALITY OF LIFE; REVIEW; SYSTEMATIC REVIEW; WNT SIGNALING PATHWAY;

CYSTS; HUMANS; LIVER DISEASES;

EID: 84901500059     PISSN: None     EISSN: 17501172     Source Type: Journal    
DOI: 10.1186/1750-1172-9-69     Document Type: Review

References (88)

1. Embryology of extra- and intrahepatic bile ducts, the ductal plate. Roskams T, Desmet V, Anat Rec (Hoboken) 2008 291 628 635
2. Biliary differentiation and bile duct morphogenesis in development and disease. Raynaud P, Carpentier R, Antoniou A, Lemaigre FP, Int J Biochem Cell Biol 2011 43 245 256
3. Development of the bile ducts: essentials for the clinical hepatologist. Strazzabosco M, Fabris L, J Hepatol 2012 56 1159 1170
4. Congenital fibrocystic liver diseases. Drenth JP, Chrispijn M, Bergmann C, Best Pract Res Clin Gastroenterol 2010 24 573 584
5. Imaging findings of biliary hamartomas. Zheng RQ, Zhang B, Kudo M, Onda H, Inoue T, World J Gastroenterol 2005 11 6354 6359 (Pubitemid 43014004)
6. A classification of ductal plate malformations based on distinct pathogenic mechanisms of biliary dysmorphogenesis. Raynaud P, Tate J, Callens C, Cordi S, Vandersmissen P, Carpentier R, Sempoux C, Devuyst O, Pierreux CE, Courtoy P, Dahan K, Delbecque K, Lepreux S, Pontoglio M, Guay-Woodford LM, Lemaigre FP, Hepatology 2011 53 1959 1966
7. Ludwig symposium on biliary disorders-part I. Pathogenesis of ductal plate abnormalities. Desmet VJ, Mayo Clin Proc 1998 73 80 89
8. Ciliopathies. Hildebrandt F, Benzing T, Katsanis N, N Engl J Med 2011 364 1533 1543
9. Cystic focal liver lesions in the adult: differential CT and MR imaging features. Mortele KJ, Ros PR, Radiographics 2001 21 895 910 (Pubitemid 33707882)
10. Bile-duct hamartomas presenting as multiple focal lesions on hepatic ultrasonography. Salo J, Bru C, Vilella A, Gines P, Gilabert R, Castells A, Bruguera M, Rodes J, Am J Gastroenterol 1992 87 221 223
11. Mechanisms of liver development: concepts for understanding liver disorders and design of novel therapies. Lemaigre FP, Gastroenterology 2009 137 62 79
12. Liver and kidney disease in ciliopathies. Gunay-Aygun M, Am J Med Genet C: Semin Med Genet 2009 151C 296 306
13. Autosomal dominant polycystic kidney disease. Torres VE, Harris PC, Pirson Y, Lancet 2007 369 1287 1301 (Pubitemid 46552051)
14. Magnetic resonance imaging evaluation of hepatic cysts in early autosomal-dominant polycystic kidney disease: the Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease cohort. Bae KT, Zhu F, Chapman AB, Torres VE, Grantham JJ, Guay-Woodford LM, Baumgarten DA, King BF Jr, Wetzel LH, Kenney PJ, Brummer ME, Bennett WM, Klahr S, Meyers CM, Zhang X, Thompson PA, Miller JP, Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP), Clin J Am Soc Nephrol 2006 1 64 69
15. Patients with isolated polycystic liver disease referred to liver centres: clinical characterization of 137 cases. Van Keimpema L, De Koning DB, Van Hoek B, Van Den Berg AP, Van Oijen MG, De Man RA, Nevens F, Drenth JP, Liver Int 2011 31 92 98
16. The hepatic von Meyenburg complex: prevalence and association with hepatic and renal cysts among 2843 autopsies [corrected]. Redston MS, Wanless IR, Mod Pathol 1996 9 233 237 (Pubitemid 26126548)
17. Fibropolycystic liver disease: CT and MR imaging findings. Brancatelli G, Federle MP, Vilgrain V, Vullierme MP, Marin D, Lagalla R, Radiographics 2005 25 3 659 670 (Pubitemid 40826785)
18. Hepatic von Meyenburg complex simulating biliary cystadenocarcinoma. Karahan OI, Kahriman G, Soyuer I, Ok E, Clin Imaging 2007 31 50 53 (Pubitemid 46001705)
19. Clinical profile of autosomal dominant polycystic liver disease. Qian Q, Li A, King BF, Kamath PS, Lager DJ, Huston J 3rd, Shub C, Davila S, Somlo S, Torres VE, Hepatology 2003 37 164 171 (Pubitemid 36042157)
20. Systematic review: the pathophysiology and management of polycystic liver disease. Temmerman F, Missiaen L, Bammens B, Laleman W, Cassiman D, Verslype C, Van Pelt J, Nevens F, Aliment Pharmacol Ther 2011 34 702 713
21. Cystic disease in women: clinical characteristics and medical management. Chapman AB, Adv Ren Replace Ther 2003 10 24 30 (Pubitemid 36278327)
22. Postmenopausal estrogen therapy selectively stimulates hepatic enlargement in women with autosomal dominant polycystic kidney disease. Sherstha R, McKinley C, Russ P, Scherzinger A, Bronner T, Showalter R, Everson GT, Hepatology 1997 26 1282 1286 (Pubitemid 27509314)
23. Risk factors for the development of hepatic cysts in autosomal dominant polycystic kidney disease. Gabow PA, Johnson AM, Kaehny WD, Manco-Johnson ML, Duley IT, Everson GT, Hepatology 1990 11 1033 1037 (Pubitemid 20221041)
24. Diagnostic approach in autosomal dominant polycystic kidney disease. Pei Y, Clin J Am Soc Nephrol 2006 1 1108 1114
25. Autosomal dominant polycystic kidney disease: modification of disease progression. Peters DJ, Breuning MH, Lancet 2001 358 1439 1444 (Pubitemid 33055752)
26. Complications arising in simple and polycystic liver cysts. Macutkiewicz C, Plastow R, Chrispijn M, Filobbos R, Ammori BA, Sherlock DJ, Drenth JP, O'Reilly DA, World J Hepatol 2012 4 406 411
27. Polycystic liver: clinical characteristics of patients with isolated polycystic liver disease compared with patients with polycystic liver and autosomal dominant polycystic kidney disease. Hoevenaren IA, Wester R, Schrier RW, McFann K, Doctor RB, Drenth JP, Everson GT, Liver Int 2008 28 264 270 (Pubitemid 351201040)
28. Hemorrhagic liver cyst rupture: an unusual life-threatening complication of hepatic cyst and literature review. Marion Y, Brevartt C, Plard L, Chiche L, Ann Hepatol 2013 12 336 339
29. Diagnosis of cyst infection in patients with autosomal dominant polycystic kidney disease: attributes and limitations of the current modalities. Jouret F, Lhommel R, Devuyst O, Annet L, Pirson Y, Hassoun Z, Kanaan N, Nephrol Dial Transplant 2012 27 3746 3751
30. Carbohydrate antigen 19-9 is extremely elevated in polycystic liver disease. Waanders E, Van Keimpema L, Brouwer JT, Van Oijen MG, Aerts R, Sweep FC, Nevens F, Drenth JP, Liver Int 2009 29 1389 1395
31. Carbohydrate antigen 19-9 as a diagnostic marker for hepatic cyst infection in autosomal dominant polycystic kidney disease. Kanaan N, Goffin E, Pirson Y, Devuyst O, Hassoun Z, Am J Kidney Dis 2010 55 916 922
32. Spontaneous rupture of nonparasitic cyst of the liver. Akriviadis EA, Steindel H, Ralls P, Redeker AG, Gastroenterology 1989 97 213 215 (Pubitemid 19191019)
33. Hepatic venous outflow obstruction in patients with polycystic liver disease: pathogenesis and treatment. Uddin W, Ramage JK, Portmann B, Wilson P, Benjamin I, Tan KC, Williams R, Gut 1995 36 142 145
34. Cholangitis and Budd Chiari syndrome as complications of simple cystic liver disease. Johnstone AJ, Turnbull LW, Allan PL, Garden OJ, HPB Surg 1993 6 223 227 discussion 227-228
35. Hepatic venous outflow obstruction in autosomal dominant polycystic kidney disease. Torres VE, Rastogi S, King BF, Stanson AW, Gross JB Jr, Nogorney DM, J Am Soc Nephrol 1994 5 1186 1192 (Pubitemid 24977100)
36. Inferior vena cava stenting: a safe and effective treatment for intractable ascites in patients with polycystic liver disease. Grams J, Teh SH, Torres VE, Andrews JC, Nagorney DM, J Gastrointest Surg 2007 11 985 990
37. Ascites in a polycystic patient. Chauveau D, Grunfeld JP, Durand F, Belghiti J, Nephrol Dial Transplant 1997 12 228 230 (Pubitemid 27046239)
38. Symptomatic nonparasitic cysts of the liver. Lai EC, Wong J, World J Surg 1990 14 452 456 (Pubitemid 20272516)
39. Intestine Transplant A: Excellent survival after liver transplantation for isolated polycystic liver disease: an European Liver Transplant Registry study. Van Keimpema L, Nevens F, Adam R, Porte RJ, Fikatas P, Becker T, Kirkegaard P, Metselaar HJ, Drenth JP, European L, Transpl Int 2011 24 1239 1245
40. Polycystic liver disease: multimodality imaging for complications and transplant evaluation. Morgan DE, Lockhart ME, Canon CL, Holcombe MP, Bynon JS, Radiographics 2006 26 1655 1668 quiz 1655
41. Comparison of phenotypes of polycystic kidney disease types 1 and 2. European PKD1-PKD2 Study Group. Hateboer N, Dijk MA V, Bogdanova N, Coto E, Saggar-Malik AK, San Millan JL, Torra R, Breuning M, Ravine D, Lancet 1999 353 103 107 (Pubitemid 29088079)
42. Hypertension in autosomal dominant polycystic kidney disease. Chapman AB, Stepniakowski K, Rahbari-Oskoui F, Adv Chronic Kidney Dis 2010 17 153 163
43. Analysis of baseline parameters in the HALT polycystic kidney disease trials. Torres VE, Chapman AB, Perrone RD, Bae KT, Abebe KZ, Bost JE, Miskulin DC, Steinman TI, Braun WE, Winklhofer FT, Hogan MC, Oskoui FR, Kelleher C, Masoumi A, Glockner J, Halin NJ, Martin DR, Remer E, Patel N, Pedrosa I, Wetzel LH, Thompson PA, Miller JP, Meyers CM, Schrier RW, HALT PKD Study Group, Kidney Int 2012 81 577 585
44. Isolated polycystic liver disease. Qian Q, Adv Chronic Kidney Dis 2010 17 181 189
45. Cardiovascular abnormalities in autosomal-dominant polycystic kidney disease. Ecder T, Schrier RW, Nat Rev Nephrol 2009 5 221 228
46. Diastolic function in several stages of chronic kidney disease in patients with autosomal dominant polycystic kidney disease: a tissue Doppler imaging study. De Almeida EA, De Oliveira EI, Lopes JA, Almeida AG, Lopes MG, Prata MM, Kidney Blood Press Res 2007 30 234 239 (Pubitemid 47076220)
47. Low prevalence of cardiac valve abnormalities in patients with autosomal dominant polycystic liver disease. Gevers TJ, De Koning DB, Van Dijk AP, Drenth JP, Liver Int 2012 32 690 692
48. The spectrum of cardiovascular abnormalities in autosomal dominant polycystic kidney disease: a 10-year follow-up in a five-generation kindred. Timio M, Monarca C, Pede S, Gentili S, Verdura C, Lolli S, Clin Nephrol 1992 37 245 251
49. Abdominal aortic aneurysms in hemodialysis patients with autosomal dominant polycystic kidney disease. Kato A, Takita T, Furuhashi M, Maruyama Y, Hishida A, Nephron 2001 88 185 186 (Pubitemid 32588877)
50. Screening for intracranial aneurysms in patients with isolated polycystic liver disease. Schievink WI, Spetzler RF, J Neurosurg 1998 89 719 721 (Pubitemid 28485529)
51. Management of cerebral aneurysms in autosomal dominant polycystic kidney disease. Pirson Y, Chauveau D, Torres V, J Am Soc Nephrol 2002 13 269 276 (Pubitemid 34042038)
52. Ultrasonographic study of pancreatic cysts in autosomal dominant polycystic kidney disease. Torra R, Nicolau C, Badenas C, Navarro S, Perez L, Estivill X, Darnell A, Clin Nephrol 1997 47 19 22 (Pubitemid 27052799)
53. Prevalence of cysts in seminal tract and abnormal semen parameters in patients with autosomal dominant polycystic kidney disease. Torra R, Sarquella J, Calabia J, Marti J, Ars E, Fernandez-Llama P, Ballarin J, Clin J Am Soc Nephrol 2008 3 790 793
54. Abdominal wall hernia in autosomal dominant polycystic kidney disease. Morris-Stiff G, Coles G, Moore R, Jurewicz A, Lord R, Br J Surg 1997 84 615 617 (Pubitemid 27208277)
55. Evaluation of colonic diverticular disease in autosomal dominant polycystic kidney disease without end-stage renal disease. Sharp CK, Zeligman BE, Johnson AM, Duley I, Gabow PA, Am J Kidney Dis 1999 34 863 868 (Pubitemid 29521702)
56. Germline mutations in PRKCSH are associated with autosomal dominant polycystic liver disease. Drenth JP, Te Morsche RH, Smink R, Bonifacino JS, Jansen JB, Nat Genet 2003 33 345 347 (Pubitemid 36278850)
57. Mutations in PRKCSH cause isolated autosomal dominant polycystic liver disease. Li A, Davila S, Furu L, Qian Q, Tian X, Kamath PS, King BF, Torres VE, Somlo S, Am J Hum Genet 2003 72 691 703 (Pubitemid 36255967)
58. Mutations in SEC63 cause autosomal dominant polycystic liver disease. Davila S, Furu L, Gharavi AG, Tian X, Onoe T, Qian Q, Li A, Cai Y, Kamath PS, King BF, Azurmendi PJ, Tahvanainen P, Kääriäinen H, Höckerstedt K, Devuyst O, Pirson Y, Martin RS, Lifton RP, Tahvanainen E, Torres VE, Somlo S, Nat Genet 2004 36 575 577 (Pubitemid 38715981)
59. Polycystic liver disease is a disorder of cotranslational protein processing. Drenth JP, Martina JA, van de Kerkhof R, Bonifacino JS, Jansen JB, Trends Mol Med 2005 11 37 42 (Pubitemid 40092673)
60. Congenital disorders of glycosylation in hepatology: the example of polycystic liver disease. Janssen MJ, Waanders E, Woudenberg J, Lefeber DJ, Drenth JP, J Hepatol 2010 52 432 440
61. Extensive mutational analysis of PRKCSH and SEC63 broadens the spectrum of polycystic liver disease. Waanders E, Te Morsche RH, De Man RA, Jansen JB, Drenth JP, Hum Mutat 2006 27 830
62. Comprehensive molecular diagnostics in autosomal dominant polycystic kidney disease. Rossetti S, Consugar MB, Chapman AB, Torres VE, Guay-Woodford LM, Grantham JJ, Bennett WM, Meyers CM, Walker DL, Bae K, Zhang QJ, Thompson PA, Miller JP, Harris PC, CRISP Consortium, J Am Soc Nephrol 2007 18 2143 2160 (Pubitemid 47041080)
63. Secondary and tertiary structure modeling reveals effects of novel mutations in polycystic liver disease genes PRKCSH and SEC63. Waanders E, Venselaar H, Te Morsche RH, De Koning DB, Kamath PS, Torres VE, Somlo S, Drenth JP, Clin Genet 2010 78 47 56
64. Identification of a locus for autosomal dominant polycystic liver disease, on chromosome 19p13.2-13.1. Reynolds DM, Falk CT, Li A, King BF, Kamath PS, Huston J 3rd, Shub C, Iglesias DM, Martin RS, Pirson Y, Torres VE, Somlo S, Am J Hum Genet 2000 67 1598 1604
65. Evaluation of ultrasonographic diagnostic criteria for autosomal dominant polycystic kidney disease 1. Ravine D, Gibson RN, Walker RG, Sheffield LJ, Kincaid-Smith P, Danks DM, Lancet 1994 343 824 827 (Pubitemid 24147512)
66. Unified criteria for ultrasonographic diagnosis of ADPKD. Pei Y, Obaji J, Dupuis A, Paterson AD, Magistroni R, Dicks E, Parfrey P, Cramer B, Coto E, Torra R, San Millan JL, Gibson R, Breuning M, Peters D, Ravine D, J Am Soc Nephrol 2009 20 205 212
67. A family with a milder form of adult dominant polycystic kidney disease not linked to the PKD1 (16p) or PKD2 (4q) genes. Ariza M, Alvarez V, Marin R, Aguado S, Lopez-Larrea C, Alvarez J, Menendez MJ, Coto E, J Med Genet 1997 34 587 589 (Pubitemid 27315641)
68. Is there a third gene for autosomal dominant polycystic kidney disease? Paterson AD, Pei Y, Kidney Int 1998 54 1759 1761 (Pubitemid 28502922)
69. Evidence for a third genetic locus for autosomal dominant polycystic kidney disease. Daoust MC, Reynolds DM, Bichet DG, Somlo S, Genomics 1995 25 733 736
70. Somatic mutation in individual liver cysts supports a two-hit model of cystogenesis in autosomal dominant polycystic kidney disease. Watnick TJ, Torres VE, Gandolph MA, Qian F, Onuchic LF, Klinger KW, Landes G, Germino GG, Mol Cell 1998 2 247 251 (Pubitemid 128373650)
71. Somatic PKD2 mutations in individual kidney and liver cysts support a "two-hit" model of cystogenesis in type 2 autosomal dominant polycystic kidney disease. Pei Y, Watnick T, He N, Wang K, Liang Y, Parfrey P, Germino G, St George-Hyslop P, J Am Soc Nephrol 1999 10 1524 1529 (Pubitemid 29297527)
72. Secondary, somatic mutations might promote cyst formation in patients with autosomal dominant polycystic liver disease. Janssen MJ, Waanders E, Te Morsche RH, Xing R, Dijkman HB, Woudenberg J, Drenth JP, Gastroenterology 2011 141 2056 2063 e2052
73. Loss of heterozygosity is present in SEC63 germline carriers with polycystic liver disease. Janssen MJ, Salomon J, Te Morsche RH, Drenth JP, PLoS ONE 2012 7 50324
74. Mutations in multiple PKD genes may explain early and severe polycystic kidney disease. Bergmann C, Von Bothmer J, Ortiz Bruchle N, Venghaus A, Frank V, Fehrenbach H, Hampel T, Pape L, Buske A, Jonsson J, Sarioglu N, Santos A, Ferreira JC, Becker JU, Cremer R, Hoefele J, Benz MR, Weber LT, Buettner R, Zerres K, J Am Soc Nephrol 2011 22 2047 2056
75. Secretion of cytokines and growth factors into autosomal dominant polycystic kidney disease liver cyst fluid. Nichols MT, Gidey E, Matzakos T, Dahl R, Stiegmann G, Shah RJ, Grantham JJ, Fitz JG, Doctor RB, Hepatology 2004 40 836 846 (Pubitemid 39288116)
76. Hepatocystin is not secreted in cyst fluid of hepatocystin mutant polycystic liver patients. Waanders E, Lameris AL, Op den Camp HJ, Pluk W, Gloerich J, Strijk SP, Drenth JP, J Proteome Res 2008 7 2490 2495
77. Morphological and functional features of hepatic cyst epithelium in autosomal dominant polycystic kidney disease. Alvaro D, Onori P, Alpini G, Franchitto A, Jefferson DM, Torrice A, Cardinale V, Stefanelli F, Mancino MG, Strazzabosco M, Angelico M, Attili A, Gaudio E, Am J Pathol 2008 172 321 332 (Pubitemid 351282020)
78. Diagnosis and management of polycystic liver disease. Gevers TJ, Drenth JP, Nat Rev Gastroenterol Hepatol 2013 10 101 108
79. Polycystic liver and kidney diseases. Tahvanainen E, Tahvanainen P, Kaariainen H, Hockerstedt K, Ann Med 2005 37 546 555 (Pubitemid 41780143)
80. Association of mutation position in polycystic kidney disease 1 (PKD1) gene and development of a vascular phenotype. Rossetti S, Chauveau D, Kubly V, Slezak JM, Saggar-Malik AK, Pei Y, Ong AC, Stewart F, Watson ML, Bergstralh EJ, Winearls CG, Torres VE, Harris PC, Lancet 2003 361 2196 2201 (Pubitemid 36782553)
81. Extra-renal manifestations of ADPKD: considerations for routine screening and management. Luciano RL, Dahl NK, Nephrol Dial Transplant 2014 29 247 254
82. Evaluating health-related quality of life in patients with polycystic liver disease and determining the impact of symptoms and liver volume. Wijnands TF, Neijenhuis MK, Kievit W, Nevens F, Hogan MC, Torres VE, Gevers TJ, Drenth JP, Liver Int 2013 doi:10.1111/liv.12430
83. The effect of caffeine on renal epithelial cells from patients with autosomal dominant polycystic kidney disease. Belibi FA, Wallace DP, Yamaguchi T, Christensen M, Reif G, Grantham JJ, J Am Soc Nephrol 2002 13 2723 2729 (Pubitemid 35216041)
84. Medical and surgical treatment options for polycystic liver disease. Drenth JP, Chrispijn M, Nagorney DM, Kamath PS, Torres VE, Hepatology 2010 52 2223 2230
85. Hepatic vein stenting for recurrent ascites in polycystic liver and kidney disease. Mudge DW, Taylor J, Bannister KM, Nephrol Dial Transplant 2005 20 2566 2568 (Pubitemid 41548893)
86. The long-term outcome of patients with polycystic liver disease treated with lanreotide. Chrispijn M, Nevens F, Gevers TJ, Vanslembrouck R, Van Oijen MG, Coudyzer W, Hoffmann AL, Dekker HM, De Man RA, Van Keimpema L, Drenth JP, Aliment Pharmacol Ther 2012 35 266 274
87. Somatostatin analog therapy for severe polycystic liver disease: results after 2 years. Hogan MC, Masyuk TV, Page L, Holmes DR 3rd, Li X, Bergstralh EJ, Irazabal MV, Kim B, King BF, Glockner JF, Larusso NF, Torres VE, Nephrol Dial Transplant 2012 27 3532 3539
88. Young women with polycystic liver disease respond best to somatostatin analogues: a pooled analysis of individual patient data. Gevers TJ, Inthout J, Caroli A, Ruggenenti P, Hogan MC, Torres VE, Nevens F, Drenth JP, Gastroenterology 2013 145 357 365 e351-352